vs
CHIMERA INVESTMENT CORP（CIM）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
CHIMERA INVESTMENT CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.9倍（$66.2M vs $35.5M），CHIMERA INVESTMENT CORP净利率更高（42.8% vs -304.2%，领先347.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 0.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 0.8%）
Chimera Investment Corp是一家总部位于美国的房地产投资信托，主要投资住宅抵押贷款支持证券、住宅及商业抵押贷款和其他房地产相关金融资产，聚焦为股东创造经风险调整的可持续回报，通过投资组合运营派发定期股息。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CIM vs RXRX — 直观对比
营收规模更大
CIM
是对方的1.9倍
$35.5M
营收增速更快
RXRX
高出681.2%
0.5%
净利率更高
CIM
高出347.1%
-304.2%
两年增速更快
RXRX
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.2M | $35.5M |
| 净利润 | $28.3M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 42.6% | -304.8% |
| 净利率 | 42.8% | -304.2% |
| 营收同比 | 0.5% | 681.7% |
| 净利润同比 | 119.3% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIMRXRX
| Q4 25 | $66.2M | $35.5M | ||
| Q3 25 | $65.0M | $5.2M | ||
| Q2 25 | $66.0M | $19.2M | ||
| Q1 25 | $69.2M | $14.7M | ||
| Q4 24 | $65.8M | $4.5M | ||
| Q3 24 | $66.5M | $26.1M | ||
| Q2 24 | $67.3M | $14.4M | ||
| Q1 24 | $65.1M | $13.8M |
净利润CIMRXRX
| Q4 25 | $28.3M | $-108.1M | ||
| Q3 25 | $-580.0K | $-162.3M | ||
| Q2 25 | $35.5M | $-171.9M | ||
| Q1 25 | $167.3M | $-202.5M | ||
| Q4 24 | $-146.5M | $-178.9M | ||
| Q3 24 | $136.5M | $-95.8M | ||
| Q2 24 | $56.7M | $-97.5M | ||
| Q1 24 | $129.5M | $-91.4M |
毛利率CIMRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率CIMRXRX
| Q4 25 | 42.6% | -304.8% | ||
| Q3 25 | -0.5% | -3327.6% | ||
| Q2 25 | 54.3% | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | -222.6% | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | 84.2% | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率CIMRXRX
| Q4 25 | 42.8% | -304.2% | ||
| Q3 25 | -0.9% | -3135.3% | ||
| Q2 25 | 53.7% | -894.2% | ||
| Q1 25 | 241.7% | -1373.3% | ||
| Q4 24 | -222.6% | -3935.5% | ||
| Q3 24 | 205.4% | -367.5% | ||
| Q2 24 | 84.2% | -676.6% | ||
| Q1 24 | 198.8% | -662.4% |
每股收益（稀释后）CIMRXRX
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $-0.27 | $-0.36 | ||
| Q2 25 | $0.17 | $-0.41 | ||
| Q1 25 | $1.77 | $-0.50 | ||
| Q4 24 | $-2.06 | $-0.56 | ||
| Q3 24 | $1.39 | $-0.34 | ||
| Q2 24 | $0.41 | $-0.40 | ||
| Q1 24 | $1.36 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $278.6M | $743.3M |
| 总债务越低越好 | $251.5M | $9.6M |
| 股东权益账面价值 | $2.6B | $1.1B |
| 总资产 | $15.8B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.10× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CIMRXRX
| Q4 25 | $278.6M | $743.3M | ||
| Q3 25 | $491.5M | $659.8M | ||
| Q2 25 | $250.2M | $525.1M | ||
| Q1 25 | $253.3M | $500.5M | ||
| Q4 24 | $84.0M | $594.4M | ||
| Q3 24 | $97.3M | $427.6M | ||
| Q2 24 | $162.3M | $474.3M | ||
| Q1 24 | $169.0M | $296.3M |
总债务CIMRXRX
| Q4 25 | $251.5M | $9.6M | ||
| Q3 25 | $251.0M | $11.9M | ||
| Q2 25 | $135.2M | $14.2M | ||
| Q1 25 | $134.9M | $16.4M | ||
| Q4 24 | $134.6M | $19.0M | ||
| Q3 24 | $134.4M | $20.5M | ||
| Q2 24 | $62.4M | $22.9M | ||
| Q1 24 | — | — |
股东权益CIMRXRX
| Q4 25 | $2.6B | $1.1B | ||
| Q3 25 | $2.6B | $1.0B | ||
| Q2 25 | $2.6B | $919.1M | ||
| Q1 25 | $2.6B | $933.9M | ||
| Q4 24 | $2.5B | $1.0B | ||
| Q3 24 | $2.7B | $524.6M | ||
| Q2 24 | $2.6B | $584.4M | ||
| Q1 24 | $2.6B | $401.2M |
总资产CIMRXRX
| Q4 25 | $15.8B | $1.5B | ||
| Q3 25 | $15.1B | $1.4B | ||
| Q2 25 | $14.9B | $1.3B | ||
| Q1 25 | $13.2B | $1.3B | ||
| Q4 24 | $13.1B | $1.4B | ||
| Q3 24 | $13.7B | $726.5M | ||
| Q2 24 | $13.1B | $775.9M | ||
| Q1 24 | $12.5B | $557.8M |
负债/权益比CIMRXRX
| Q4 25 | 0.10× | 0.01× | ||
| Q3 25 | 0.10× | 0.01× | ||
| Q2 25 | 0.05× | 0.02× | ||
| Q1 25 | 0.05× | 0.02× | ||
| Q4 24 | 0.05× | 0.02× | ||
| Q3 24 | 0.05× | 0.04× | ||
| Q2 24 | 0.02× | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-248.9M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | -8.78× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CIMRXRX
| Q4 25 | $-248.9M | $-46.1M | ||
| Q3 25 | $-137.5M | $-117.4M | ||
| Q2 25 | $-7.4M | $-76.4M | ||
| Q1 25 | $48.8M | $-132.0M | ||
| Q4 24 | $205.7M | $-115.4M | ||
| Q3 24 | $41.4M | $-59.2M | ||
| Q2 24 | $69.0M | $-82.2M | ||
| Q1 24 | $57.3M | $-102.3M |
自由现金流CIMRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率CIMRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度CIMRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率CIMRXRX
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
